QuiaPEG Pharmaceuticals AB develops proprietary, releasable PEGylation technologies (Uni-Qleaver®) for the development of prodrugs and biobetters with improved pharmacological properties, e.g. extended half-life and increased tolerability.
The release mechanism of the PEG-chain from the active drug substance can be either pH- or enzyme-dependent and allows for controlled and complete release of the active substance, with customizable release half-life ranging from hours to weeks.